Mesa Laboratories, Inc (MLAB) Fair Value & Analysis
Technology · US · Market cap $525M
Mesa Laboratories, Inc
MLAB · US
Fair value as of: Jul 19, 2026
From 26 valuation models · updated 22 days ago
Share price +12.4% over the past month.
A solid business, but screening 74% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case ($33.41). The favourable scenario is already priced in.
- Solid but not exceptional quality (62/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range ($17.66 to $33.41) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 19, 2026.
How to read this chart
60‑month range $57.01 – $324.48 · fair‑value band $17.66 – $33.41 · the $102.65 price screens above the $26.73 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 19, 2026.
Analysis
Mesa Laboratories, Inc (MLAB) currently trades at $102.65, while our model-based Fair Value estimate is $26.73, implying the stock looks roughly 74.0% overvalued today. The Quality Score stands at 62/100 (solid quality), in the Technology sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Mesa Laboratories, Inc generated revenue of $249M at a net margin of 2.7%. Revenue grew 2.6% year over year. It earns a return on equity of 3.9%. Net debt stands at $142M. Fundamentals as of Jul 19, 2026
Our scenario range runs from $17.66 (bear case) to $33.41 (bull case); at $102.65, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 10% below its 52-week high and 87% above its 52-week low, currently above its 200-day average. For context, the median of 10 Technology peers we cover trades at -45% fair-value upside, at -74%, MLAB screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models ($64.76) versus Economic Profit ($0.2100). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 19, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 58 · Market factors (momentum, volatility) 60
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally.
Full company description
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Mesa Laboratories, Inc reported revenue of $249M in FY2026 versus $184M in FY2022, a compound +7.8%/yr. Reported net income was $6.7M in FY2026, compounding +37.6%/yr from FY2022.
MLAB screens 74% overvalued. Compare with Keysight Technologies, Inc →
Earlier news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- Mesa Laboratories declares $0.16 dividend
- Why Mesa Laboratories Stock Is Getting Hit With a Huge Sell-Off Today
Peer Group
Scientific & Technical Instruments · 161 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Scientific & Technical Instruments median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Insider activity: 86/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Scientific & Technical Instruments stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Keysight Technologies, Inc KEYS | $315.90 | $84.16 | -73% |
| Garmin Ltd GRMN | $241.76 | $146.67 | -39% |
| Teledyne Technologies Incorporated TDY | $635.52 | $367.58 | -42% |
| Chroma ATE Inc 2360 | 1,905 TWD | 286.15 TWD | -85% |
| Hexagon AB HEXAB | kr 80.10 | kr 52.93 | -34% |
| MKS Inc MKSI | $324.69 | $77.46 | -76% |
| AVIC Chengdu Aircraft Company 302132 | ¥52.91 | ¥34.47 | -35% |
| Fortive Corporation FTV | $61.78 | $33.84 | -45% |
| Trimble Inc TRMB | $52.72 | $24.47 | -54% |
| Cognex Corporation CGNX | $64.07 | $13.75 | -79% |
Compare Mesa Laboratories, Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Technology stocks →
Frequently asked questions
Is Mesa Laboratories, Inc (MLAB) overvalued or undervalued?
What is the fair value of MLAB?
What is the quality score of MLAB?
What is the revenue of Mesa Laboratories, Inc (MLAB)?
What is the net profit margin of MLAB?
Does Mesa Laboratories, Inc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Mesa Laboratories, Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.